BR112021025487A2 - Peptídeos restritos - Google Patents

Peptídeos restritos

Info

Publication number
BR112021025487A2
BR112021025487A2 BR112021025487A BR112021025487A BR112021025487A2 BR 112021025487 A2 BR112021025487 A2 BR 112021025487A2 BR 112021025487 A BR112021025487 A BR 112021025487A BR 112021025487 A BR112021025487 A BR 112021025487A BR 112021025487 A2 BR112021025487 A2 BR 112021025487A2
Authority
BR
Brazil
Prior art keywords
restricted
restricted peptides
peptide
peptides
kits
Prior art date
Application number
BR112021025487A
Other languages
English (en)
Inventor
W Laurie Gordon
A Laskar Paul
R Gadek Thomas
Original Assignee
Tearsolutions Inc
The Univ Of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tearsolutions Inc, The Univ Of Virginia Patent Foundation filed Critical Tearsolutions Inc
Publication of BR112021025487A2 publication Critical patent/BR112021025487A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

peptídeos restritos. em geral, este pedido refere-se a sais restritos de peptídeos, formas restritas de peptídeos e composições, kits, métodos de uso ou usos dos mesmos.
BR112021025487A 2019-06-19 2020-06-17 Peptídeos restritos BR112021025487A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863651P 2019-06-19 2019-06-19
US201962863666P 2019-06-19 2019-06-19
PCT/US2020/038205 WO2020257327A1 (en) 2019-06-19 2020-06-17 Constrained peptides

Publications (1)

Publication Number Publication Date
BR112021025487A2 true BR112021025487A2 (pt) 2022-05-17

Family

ID=74040887

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025487A BR112021025487A2 (pt) 2019-06-19 2020-06-17 Peptídeos restritos

Country Status (10)

Country Link
US (1) US20240294573A1 (pt)
EP (1) EP3986914A4 (pt)
JP (1) JP2022537383A (pt)
KR (1) KR20220044719A (pt)
CN (1) CN114206916A (pt)
AU (1) AU2020298164A1 (pt)
BR (1) BR112021025487A2 (pt)
CA (1) CA3143676A1 (pt)
MX (1) MX2021015879A (pt)
WO (1) WO2020257327A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023215269A1 (en) * 2022-05-06 2023-11-09 The Regents Of The University Of California Lacripep promotes neuroregeneration and maintains epithelial progenitor cell identity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
WO2011138228A1 (en) * 2010-05-04 2011-11-10 Trb Chemedica Ag Aqueous composition for ophthalmic or dermal use
JP7223712B2 (ja) * 2017-02-21 2023-02-16 ティアソリューションズ・インコーポレイテッド 安定なペプチド組成物

Also Published As

Publication number Publication date
AU2020298164A1 (en) 2022-02-03
EP3986914A1 (en) 2022-04-27
MX2021015879A (es) 2022-07-04
CN114206916A (zh) 2022-03-18
CA3143676A1 (en) 2020-12-24
KR20220044719A (ko) 2022-04-11
JP2022537383A (ja) 2022-08-25
EP3986914A4 (en) 2023-07-19
US20240294573A1 (en) 2024-09-05
WO2020257327A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
CL2021000738A1 (es) Proteínas de fijación a sirpa y métodos de uso de estas
BR112021024224A2 (pt) Inibidores de tead e usos dos mesmos
CL2021000704A1 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019)
BR112017002594A2 (pt) compostos inibidores de cinase de ligação de tank
BR112016026773A2 (pt) domínios variáveis de imunoglobulina aperfeiçoados
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
BR112019013468A8 (pt) Anticorpos anti-hiv-1 amplamente neutralizante e métodos de uso dos mesmos
BR112022000122A2 (pt) Compostos que compreendem um ligante de proteína de ativação de fibroblasto e uso dos mesmos
CL2013003090A1 (es) Polipeptido que comprende una primera secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17f, il17-a/f, pero no a il-17a, y una segunda secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17a, il-17f y il17-a/f; composicion farmaceutica que lo comprende; y su uso.
BR112022012410A2 (pt) Degradadores smarca e usos dos mesmos
BR112015026847A2 (pt) tiazóis e usos dos mesmos
CL2008001467A1 (es) Peptidos cilindricos antagonistas de cxcr4 ciclado por lactamas: composicion farmaceutica que los comprenden; y su uso para tratar artitis reumatica, fibrosis pulmonar, infeccion por vih o cancer.
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
CL2021000855A1 (es) Replicones basados en alfavirus para la administración de bioterapias.
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
BR112022010143A2 (pt) Inibidores de ahr e usos respectivos
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
BR112023023223A2 (pt) Degradadores de cdk2 e usos dos mesmos
BR112022010153A2 (pt) Peptídeos, ácido nucleico, polipeptídeo, composição, complexo bioluminescente, métodos, dipeptídeo, sistema e kit
BR112021025487A2 (pt) Peptídeos restritos
PH12017501914A1 (en) Polypeptides targeting hiv fusion
EA202191137A1 (ru) Способы анализа композиции вирусного капсидного белка
CY1124507T1 (el) Νεος αναστολεας μεκ για τη θεραπευτικη αγωγη των ιικων και βακτηριακων λοιμωξεων